For how long must male patients of reproductive potential and their female partners of childbearing potential use barrier contraception after etranacogene dezaparvovec (Hemgenix) treatment?

Male patients of reproductive potential treated with etranacogene dezaparvovec (Hemgenix) and their female partners of childbearing potential must use barrier contraception to prevent or postpone pregnancy for 12 months after administration.